Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist
drug action, resulting in increased side effects following drug treatment. A novel therapeutic …

Recently, the demand for food proteins in the market has increased due to a rise in
degenerative illnesses that are associated with the excessive production of free radicals and …

Toxicity emerges as a prominent challenge in the design of therapeutic peptides, causing
the failure of numerous peptides during clinical trials. In 2013, our group developed …

Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

Nearly one in six people worldwide suffer from disorders of the central nervous system
(CNS). There is an urgent need for effective strategies to improve the success rates in CNS …

In recent years, the occurrence of a wide variety of drug-resistant diseases has led to an
increase in interest in alternate therapies. Peptide-based drugs as an alternate therapy hold …

Cancer remains the leading cause of death worldwide despite advances in treatment
options for patients. As such, safe and effective therapeutics are required. Short peptides …

Efficient intracellular trafficking and targeted delivery to the site of action are essential to
overcome the current drawbacks of cancer therapeutics. Cell Penetrating Peptides (CPPs) …

Abstract CancerPPD (http://crdd. osdd. net/raghava/cancerppd/) is a repository of
experimentally verified anticancer peptides (ACPs) and anticancer proteins. Data were …

Peptide therapy has started since 1920s with the advent of insulin application, and now it
has emerged as a new approach in treatment of diseases including cancer. Using anti …